Physician profile
Ryan Gunderman
NPI 1548950678
$2,008.18
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $509 · 2024: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.90 | 2023-2024 | |
| Pfizer INC. | $325.87 | 2024 | |
| Lilly USA, LLC | $245.23 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $188.96 | 2024 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $136.09 | 2023 | |
| Viiv Healthcare Company | $87.87 | 2024 | Apretude |
| Novo Nordisk INC | $75.29 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.09 | 2023-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $64.71 | 2023-2024 | |
| Esperion Therapeutics, INC. | $55.34 | 2024 | Nexletol |
| Paratek Pharmaceuticals, INC. | $45.88 | 2024 | Nuzyra |
| Boston Scientific Corporation | $44.67 | 2023 | Bodyguardian |
| Hologic Sales and Service, LLC | $44.57 | 2023 | Aptima |
| Sumitomo Pharma America, INC. | $37.13 | 2024 | Gemtesa |
| Seqirus USA INC | $32.86 | 2024 | Flucelvax, Fluad |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2024 | |
| Radius Health, INC. | $22.25 | 2024 | Tymlos |
| Eisai INC. | $21.27 | 2023 | |
| Glaxosmithkline, LLC. | $20.69 | 2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $14.94 | 2023 | Cologuard Collection Kit |
| Acarix USA INC. | $11.34 | 2024 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gunderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.